Turing CEO Martin Shkreli reveals how passive voice is the last refuge of a scoundrel
Martin Shkreli, the CEO of Turing Pharmaceuticals, announced a huge increase in the cost of his drug for a life-threatening disease. Then he backtracked. By analyzing his passive statements, you see exactly how a scoundrel evades responsibility. After acquiring the drug Daraprim, used to treat the sometimes deadly parasitic infection toxoplasmosis, Turing Pharmaceuticals hiked the price from $13.50 to…